Clinical Trial

Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth

Not Yet Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The primary objective of the study is to assess the safety and efficacy of DA-001 as a treatment for Hair Shedding Reduction and Hair Re-Growth
Protocol Amendment History 3 changes
notable Enrollment increased: 800 -> 1120 participants 2026-04-14
minor Trial arms changed: 5 -> 7 2026-04-14
minor Completion pushed: 2027-03-26 -> 2027-04-26 2026-04-14
Trial Details
NCT Number NCT06648850
Lead Sponsor Applied Biology, Inc.
Collaborators: Follea International Limited, Daniel Alain, Inc.
Conditions Telogen Effluvium, Female Pattern Hair Loss, Female Pattern Hair Loss, Androgenic Alopecia, Male Pattern Baldness, Androgenetic Alopecia, Androgenetic Alopecia (AGA)
Enrollment 1,120 participants
Start Date 2026-05-01
Primary Completion 2027-03-19 (estimated)
Study Completion 2027-04-26 (estimated)
Updated on ClinicalTrials.gov 2026-04-13